Saving your money for next purchases
Brigatinib布加替尼 ，Brigatinib，布吉他滨,布格替尼
Bukitabine was approved by the FDA on April 28, 2017 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) with disease progression or intolerance after crizotinib treatment.
Bujibine is a tyrosine kinase inhibitor that can inhibit abnormal activation caused by ALK fusion and inhibit tumor cell proliferation.
Share:
Products
Our offers
Delivery – when you want and anywhere
A huge selection of best products
Health Classification
Let us work together to protect precious health
